microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production

Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects cholesterol homeostasis by targeting hepatic LDL receptor (LDLR) for lysosomal degradation. Clinically, PCSK9 inhibitors effectively reduce LDL-cholesterol (LDL-C) levels and the incidence of cardiovascular events. Because microRNAs (miRs...

Full description

Bibliographic Details
Main Authors: Jianjie Dong, Ming He, Jie Li, Ariane Pessentheiner, Chen Wang, Jin Zhang, Yameng Sun, Wei-Ting Wang, Yuqing Zhang, Junhui Liu, Shen-Chih Wang, Po-Hsun Huang, Philip L.S.M. Gordts, Zu-Yi Yuan, Sotirios Tsimikas, John Y.J. Shyy
Format: Article
Language:English
Published: American Society for Clinical investigation 2020-12-01
Series:JCI Insight
Subjects:
Metabolism
Vascular biology
Online Access:https://doi.org/10.1172/jci.insight.143812

Internet

https://doi.org/10.1172/jci.insight.143812

Similar Items